# OrsoBio

> OrsoBio is a Palo Alto clinical-stage biopharmaceutical company developing first-in-class small-molecule therapies for severe metabolic disorders including obesity, type 2 diabetes, and MASH. Its lead approach uses liver-targeted mitochondrial protonophores that restore cellular energy homeostasis - biology inspired partly by how hibernating bears manage their metabolism ("orso" is Italian for bear). Incubated by Samsara BioCapital and led by former Gilead liver-disease leaders, the company has raised roughly $256M across four rounds and reported Phase 1b/2a data showing its lead candidate TLC-6740 added meaningful weight loss on top of the incretin drug tirzepatide.

- **Founded:** 2021
- **Headquarters:** Palo Alto, California, United States
- **Founders:** Mani Subramanian (Co-Founder & CEO), Gans Ganapati (Co-Founder & Chief Business and Financial Officer)
- **Team size:** ~19 employees
- **Products:** TLC-6740, TLC-1180, TLC-1235, Human liver organoid platform
- **Notable:** Raised approximately $256M in total funding across four rounds, Closed an oversubscribed $67M Series B in September 2024, Reported positive Phase 1b/2a data: 13.3% weight loss with TLC-6740 + tirzepatide vs 8.8% with tirzepatide alone

## Products & services

- **TLC-6740** — A novel, oral, liver-targeted mitochondrial protonophore, the company's lead candidate, evaluated for obesity and metabolic disorders including in combination with incretin (GLP-1/GIP) therapy such as tirzepatide.
- **TLC-1180** — A next-generation protonophore with greater systemic distribution, in IND-enabling development.
- **TLC-1235** — A next-generation protonophore with distinct attributes versus TLC-6740, in IND-enabling development.
- **Human liver organoid platform** — A discovery platform used to optimize compound development and study metabolic disease biology.

## Achievements

- Raised approximately $256M in total funding across four rounds
- Closed an oversubscribed $67M Series B in September 2024
- Reported positive Phase 1b/2a data: 13.3% weight loss with TLC-6740 + tirzepatide vs 8.8% with tirzepatide alone
- Demonstrated weight loss with preservation of lean muscle mass in an MRI substudy
- Built a portfolio of three differentiated mitochondrial protonophores

## Latest updates

- **2025-12** — Reported positive topline Phase 1b/2a data for TLC-6740 in combination with tirzepatide, showing greater weight loss and lean-mass preservation.
- **2025-01** — Advancing IND-enabling studies for next-generation protonophores TLC-1180 and TLC-1235.
- **2024-09** — Closed oversubscribed $67M Series B co-led by Ascenta Capital and Woodline Partners.

## Links

- Website: https://orsobio.com
- LinkedIn: http://www.linkedin.com/company/orsobio
- Twitter/X: https://twitter.com/OrsoBio

---

Profile page: https://yespress.io/orsobio
Published by YesPress — https://yespress.io
Last updated: 2026-07-11